382 related articles for article (PubMed ID: 27228211)
1. Further understanding of the pathology of glioma: implications for the clinic.
Camelo-Piragua S; Kesari S
Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
3. Pathology and Genetics of Gliomas.
Komori T; Muragaki Y; Chernov MF
Prog Neurol Surg; 2018; 31():1-37. PubMed ID: 29393190
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
7. Characterization of gliomas: from morphology to molecules.
Ferris SP; Hofmann JW; Solomon DA; Perry A
Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
[TBL] [Abstract][Full Text] [Related]
8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
9. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
Appin CL; Brat DJ
Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
[TBL] [Abstract][Full Text] [Related]
11. Glioma.
Weller M; Wick W; Aldape K; Brada M; Berger M; Pfister SM; Nishikawa R; Rosenthal M; Wen PY; Stupp R; Reifenberger G
Nat Rev Dis Primers; 2015 Jul; 1():15017. PubMed ID: 27188790
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in subtyping tumors of the central nervous system using molecular data.
Schittenhelm J
Expert Rev Mol Diagn; 2017 Jan; 17(1):83-94. PubMed ID: 27893285
[TBL] [Abstract][Full Text] [Related]
13. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
14. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Velázquez Vega JE; Brat DJ
Adv Anat Pathol; 2018 May; 25(3):143-171. PubMed ID: 29521646
[TBL] [Abstract][Full Text] [Related]
17. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
19. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
20. Cortical ependymoma or monomorphous angiocentric glioma?
Lum DJ; Halliday W; Watson M; Smith A; Law A
Neuropathology; 2008 Feb; 28(1):81-6. PubMed ID: 18021197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
